| 9.05 0.545 (6.41%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.56 |
1-year : | 13.51 |
| Resists | First : | 9.9 |
Second : | 11.56 |
| Pivot price | 9.25 |
|||
| Supports | First : | 8.66 |
Second : | 7.9 |
| MAs | MA(5) : | 9.26 |
MA(20) : | 9.23 |
| MA(100) : | 8.46 |
MA(250) : | 8.98 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 57 |
D(3) : | 64.4 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 17.44 | Low : | 6.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACET ] has closed above bottom band by 35.5%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.45 - 9.51 | 9.51 - 9.57 |
| Low: | 8.33 - 8.4 | 8.4 - 8.45 |
| Close: | 8.96 - 9.07 | 9.07 - 9.15 |
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Tue, 15 Sep 2026
Adicet Bio (ACET): The Countdown To Prula-cel Data - RTTNews
Thu, 03 Sep 2026
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wed, 02 Sep 2026
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Tue, 01 Sep 2026
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Mon, 31 Aug 2026
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Sat, 29 Aug 2026
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 64.6 (%) |
| Shares Short | 262 (K) |
| Shares Short P.Month | 383 (K) |
| EPS | -10.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.7 % |
| Return on Equity (ttm) | -78.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.87 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|